{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:05:34Z","timestamp":1743091534424,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":60,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071610077"},{"type":"electronic","value":"9781071610084"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-1008-4_15","type":"book-chapter","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T23:15:57Z","timestamp":1613776557000},"page":"203-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting"],"prefix":"10.1007","author":[{"given":"Rika","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"issue":"363","key":"15_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.363.541","volume":"2","author":"Duchenne","year":"1867","unstructured":"Duchenne (1867) The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br Med J 2(363):541\u2013542","journal-title":"Br Med J"},{"issue":"9","key":"15_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","volume":"5","author":"KJ Nowak","year":"2004","unstructured":"Nowak KJ, Davies KE (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5(9):872\u2013876. https:\/\/doi.org\/10.1038\/sj.embor.7400221","journal-title":"EMBO Rep"},{"issue":"3","key":"15_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ et al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50(3):509\u2013517","journal-title":"Cell"},{"issue":"7","key":"15_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp.2008.158329","volume":"80","author":"AY Manzur","year":"2009","unstructured":"Manzur AY, Muntoni F (2009) Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 80(7):706\u2013714. https:\/\/doi.org\/10.1136\/jnnp.2008.158329","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"15_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ (2015) Duchenne muscular dystrophy. J Paediatr Child Health 51(8):759\u2013764. https:\/\/doi.org\/10.1111\/jpc.12868","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"15_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/brainsci5030275","volume":"5","author":"B Nichols","year":"2015","unstructured":"Nichols B, Takeda S, Yokota T (2015) Nonmechanical roles of dystrophin and associated proteins in exercise, neuromuscular junctions, and brains. Brain Sci 5(3):275\u2013298. https:\/\/doi.org\/10.3390\/brainsci5030275","journal-title":"Brain Sci"},{"issue":"6","key":"15_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928","journal-title":"Cell"},{"issue":"6202","key":"15_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/337076a0","volume":"337","author":"U Nudel","year":"1989","unstructured":"Nudel U, Zuk D, Einat P et al (1989) Duchenne muscular dystrophy gene product is not identical in muscle and brain. Nature 337(6202):76\u201378. https:\/\/doi.org\/10.1038\/337076a0","journal-title":"Nature"},{"key":"15_CR9","first-page":"30","volume":"27","author":"K Sato","year":"2008","unstructured":"Sato K, Yokota T, Ichioka S et al (2008) Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. Acta Myol 27:30\u201336","journal-title":"Acta Myol"},{"issue":"7221","key":"15_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature07414","volume":"456","author":"YM Kobayashi","year":"2008","unstructured":"Kobayashi YM, Rader EP, Crawford RW et al (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456(7221):511\u2013515","journal-title":"Nature"},{"issue":"11 Suppl","key":"15_CR11","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1097\/01.PHM.0000029775.54830.80","volume":"81","author":"BJ Petrof","year":"2002","unstructured":"Petrof BJ (2002) Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 81(11 Suppl):S162\u2013S174. https:\/\/doi.org\/10.1097\/01.PHM.0000029775.54830.80","journal-title":"Am J Phys Med Rehabil"},{"issue":"4","key":"15_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10072-019-03764-z","volume":"40","author":"G Vita","year":"2019","unstructured":"Vita G, Vita GL, Musumeci O et al (2019) Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurol Sci 40(4):671\u2013681. https:\/\/doi.org\/10.1007\/s10072-019-03764-z","journal-title":"Neurol Sci"},{"issue":"6","key":"15_CR13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1172\/JCI115244","volume":"87","author":"M Matsuo","year":"1991","unstructured":"Matsuo M, Masumura T, Nishio H et al (1991) Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. J Clin Invest 87(6):2127\u20132131. https:\/\/doi.org\/10.1172\/JCI115244","journal-title":"J Clin Invest"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-1-61779-767-5_20","volume":"867","author":"Y Hua","year":"2012","unstructured":"Hua Y, Krainer AR (2012) Antisense-mediated exon inclusion. Methods Mol Biol 867:307\u2013323. https:\/\/doi.org\/10.1007\/978-1-61779-767-5_20","journal-title":"Methods Mol Biol"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","volume":"1828","author":"M Rodrigues","year":"2018","unstructured":"Rodrigues M, Yokota T (2018) An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol 1828:31\u201355. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_2","journal-title":"Methods Mol Biol"},{"issue":"6","key":"15_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030109","volume":"3","author":"M Wood","year":"2007","unstructured":"Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3(6):e109. https:\/\/doi.org\/10.1371\/journal.pgen.0030109","journal-title":"PLoS Genet"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","volume":"87","author":"R Kole","year":"2015","unstructured":"Kole R, Krieg AM (2015) Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev 87:104\u2013107. https:\/\/doi.org\/10.1016\/j.addr.2015.05.008","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"15_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","volume":"7","author":"MGMM Dunckley","year":"1998","unstructured":"Dunckley MGMM, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7(7):1083\u20131090","journal-title":"Hum Mol Genet"},{"issue":"1","key":"15_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0960-8966(93)90037-K","volume":"3","author":"DR Love","year":"1993","unstructured":"Love DR, Byth BC, Tinsley JM et al (1993) Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. Neuromuscul Disord 3(1):5\u201321","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"15_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"7","key":"15_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N et al (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. https:\/\/doi.org\/10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"3","key":"15_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"15_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ, Echigoya Y, Nagata T et al (2019) Efficacy of multi-exon skipping treatment in duchenne muscular dystrophy dog model neonates. Mol Ther 27(1):76\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.011","journal-title":"Mol Ther"},{"issue":"1","key":"15_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"15_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"issue":"3","key":"15_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s10038-017-0400-0","volume":"63","author":"T Shimo","year":"2018","unstructured":"Shimo T, Hosoki K, Nakatsuji Y et al (2018) A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR\/Cas9. J Hum Genet 63(3):365\u2013375","journal-title":"J Hum Genet"},{"issue":"Suppl 1","key":"15_CR27","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","volume":"12","author":"A Aartsma-Rus","year":"2002","unstructured":"Aartsma-Rus A, Bremmer-Bout M, Janson AA et al (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12(Suppl 1):S71\u2013S77","journal-title":"Neuromuscul Disord"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-4939-7374-3_9","volume":"1687","author":"S Miyatake","year":"2018","unstructured":"Miyatake S, Mizobe Y, Takizawa H et al (2018) Exon Skipping therapy using phosphorodiamidate morpholino oligomers in the mdx52 mouse model of Duchenne muscular dystrophy. Methods Mol Biol 1687:123\u2013141. https:\/\/doi.org\/10.1007\/978-1-4939-7374-3_9","journal-title":"Methods Mol Biol"},{"issue":"1","key":"15_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2017.1250880","volume":"17","author":"S Fletcher","year":"2017","unstructured":"Fletcher S, Bellgard MI, Price L et al (2017) Translational development of splice-modifying antisense oligomers. Expert Opin Biol Ther 17(1):15\u201330. https:\/\/doi.org\/10.1080\/14712598.2017.1250880","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"15_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Krieg AM (2017) FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther 27(1):1\u20133. https:\/\/doi.org\/10.1089\/nat.2016.0657","journal-title":"Nucleic Acid Ther"},{"issue":"11","key":"15_CR31","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/mt.2016.188","volume":"24","author":"CA Stein","year":"2016","unstructured":"Stein CA (2016) Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice. Mol Ther 24(11):1884\u20131885. https:\/\/doi.org\/10.1038\/mt.2016.188","journal-title":"Mol Ther"},{"issue":"20","key":"15_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S et al (2018) Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 91(20):923\u2013933. https:\/\/doi.org\/10.1212\/WNL.0000000000006502","journal-title":"Neurology"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"15_CR34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1474-4422(09)70229-7","volume":"8","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, van Ommen GJ (2009) Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 8(10):873\u2013875. https:\/\/doi.org\/10.1016\/S1474-4422(09)70229-7","journal-title":"Lancet Neurol"},{"issue":"6","key":"15_CR35","first-page":"2471","volume":"8","author":"Y Shimizu-Motohashi","year":"2016","unstructured":"Shimizu-Motohashi Y, Miyatake S, Komaki H et al (2016) Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res 8(6):2471\u20132489","journal-title":"Am J Transl Res"},{"issue":"6","key":"15_CR36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14712598.7.6.831","volume":"7","author":"T Yokota","year":"2007","unstructured":"Yokota T, Pistilli E, Duddy W et al (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7(6):831\u2013842. https:\/\/doi.org\/10.1517\/14712598.7.6.831","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"15_CR37","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25(11):2561\u20132572. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"key":"15_CR38","doi-asserted-by":"publisher","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today 56:491\u2013504.\u00a0https:\/\/doi.org\/10.1016\/j.omtn.2018.09.017","DOI":"10.1016\/j.omtn.2018.09.017"},{"key":"15_CR39","doi-asserted-by":"publisher","unstructured":"Roshmi RR, Yokota T (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55(10):627\u2013639. https:\/\/doi.org\/10.3390\/jpm9010001","DOI":"10.3390\/jpm9010001"},{"issue":"1","key":"15_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T (2018) Skipping multiple exons to treat DMD-promises and challenges. Biomedicine 6(1):1. https:\/\/doi.org\/10.3390\/biomedicines6010001","journal-title":"Biomedicine"},{"issue":"1","key":"15_CR41","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7(1):3672. https:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"key":"15_CR42","first-page":"57530","volume":"135","author":"R Maruyama","year":"2018","unstructured":"Maruyama R, Touznik A, Yokota T (2018) Evaluation of exon inclusion induced by splice switching antisense oligonucleotides in SMA patients fibroblasts. J Vis Exp 135:57530","journal-title":"J Vis Exp"},{"key":"15_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"15_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2018.0747","volume":"29","author":"MJ Gait","year":"2019","unstructured":"Gait MJ, Arzumanov AA, McClorey G et al (2019) Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucleic Acid Ther 29(1):1\u201312. https:\/\/doi.org\/10.1089\/nat.2018.0747","journal-title":"Nucleic Acid Ther"},{"issue":"39","key":"15_CR45","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A 113(39):10962\u201310967. https:\/\/doi.org\/10.1073\/pnas.1605731113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts C, Saleh AF, Arzumanov AA et al (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38. https:\/\/doi.org\/10.1038\/mtna.2012.30","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"15_CR47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/mt.2011.79","volume":"19","author":"H Yin","year":"2011","unstructured":"Yin H, Saleh AF, Betts C et al (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19(7):1295\u20131303. https:\/\/doi.org\/10.1038\/mt.2011.79","journal-title":"Mol Ther"},{"issue":"4","key":"15_CR48","first-page":"478","volume":"12","author":"SM Hammond","year":"2010","unstructured":"Hammond SM, Wood MJ (2010) PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther 12(4):478\u2013486","journal-title":"Curr Opin Mol Ther"},{"issue":"16","key":"15_CR49","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"15_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ et al (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346. https:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4939-8651-4_16","volume":"1828","author":"D Melo","year":"2018","unstructured":"Melo D, Maruyama R, Yokota T (2018) Systemic injection of peptide-PMOs into humanized DMD mice and evaluation by RT-PCR and ELISA. Methods Mol Biol 1828:263\u2013273. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_16","journal-title":"Methods Mol Biol"},{"issue":"2","key":"15_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ymthe.2004.05.031","volume":"10","author":"M Bremmer-Bout","year":"2004","unstructured":"Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ et al (2004) Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10(2):232\u2013240. https:\/\/doi.org\/10.1016\/j.ymthe.2004.05.031","journal-title":"Mol Ther"},{"issue":"2","key":"15_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbrc.2004.12.191","volume":"328","author":"H Kudoh","year":"2005","unstructured":"Kudoh H, Ikeda H, Kakitani M et al (2005) A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system. Biochem Biophys Res Commun 328(2):507\u2013516. https:\/\/doi.org\/10.1016\/j.bbrc.2004.12.191","journal-title":"Biochem Biophys Res Commun"},{"issue":"4912","key":"15_CR54","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski P, Geng Y, Ryder-Cook AS et al (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244(4912):1578\u20131580","journal-title":"Science"},{"issue":"4","key":"15_CR55","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0002-9440(10)65354-0","volume":"154","author":"LV Anderson","year":"1999","unstructured":"Anderson LV, Davison K (1999) Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 154(4):1017\u20131022. https:\/\/doi.org\/10.1016\/S0002-9440(10)65354-0","journal-title":"Am J Pathol"},{"issue":"22","key":"15_CR56","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","volume":"83","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Taylor LE et al (2014) Dystrophin quantification: Biological and translational research implications. Neurology 83(22):2062\u20132069. https:\/\/doi.org\/10.1212\/WNL.0000000000001025","journal-title":"Neurology"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"53776","DOI":"10.3791\/53776","volume":"111","author":"B Miskew Nichols","year":"2016","unstructured":"Miskew Nichols B, Aoki Y, Kuraoka M et al (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Vis Exp 111:53776. https:\/\/doi.org\/10.3791\/53776","journal-title":"J Vis Exp"},{"issue":"3","key":"15_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L et al (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058. https:\/\/doi.org\/10.1371\/journal.pone.0120058","journal-title":"PLoS One"},{"key":"15_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-1-4939-8651-4_23","volume":"1828","author":"R Maruyama","year":"2018","unstructured":"Maruyama R, Aoki Y, Takeda S et al (2018) In vivo evaluation of multiple exon skipping with peptide-PMOs in cardiac and skeletal muscles in Dystrophic dogs. Methods Mol Biol 1828:365\u2013379. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_23","journal-title":"Methods Mol Biol"},{"key":"15_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-8651-4_7","volume":"1828","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yokota T (2018) Quantitative evaluation of exon skipping in immortalized muscle cells in vitro. Methods Mol Biol 1828:127\u2013139. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_7","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Mouse Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1008-4_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T23:51:49Z","timestamp":1613778709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-1008-4_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9781071610077","9781071610084"],"references-count":60,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1008-4_15","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"20 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}